Probiotics in the prevention of lung infection in patients on a ventilator.

A randomized controlled trial on probiotics in prevention of ventilator-associated pneumonia in patients requiring mechanical ventilation admitted in medical department in a tertiary care center - PVAP

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018659

Enrollment

276

Registered

2019-04-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J159- Unspecified bacterial pneumonia

Interventions

Intervention1: Probiotic VSL #3 along with standard ICU care: VSL #3 contains probiotic bacterial strains of lactobacillus,bifidobacterium and streptococcus. The drug will be given for the entire dur

Eligibility

Inclusion criteria

Inclusion criteria: A Patients under department of medicine B Requiring mechanical ventilation in medical wards, MHDU or MICU for more than 2 day C Patients relatives are willing to provide informed consent.

Exclusion criteria

Exclusion criteria: A. Patientâ??s relatives not willing for informed consent.

Design outcomes

Primary

Measure	Time frame
Ventilator associated pneumonia as defined by CDC guidelinesTimepoint: PATIENT WILL BE ASSESSED DAILY FOR DEVELOPING NEW VENTILATOR ASSOCIATED PNEUMONIA	—

Secondary

Measure	Time frame
1 mortality in each admission 2 3 month mortality 3 side effects each admission 4 cost benefit analysis Timepoint: 10-30 days;5 no of ventilated days 6 reintubation ratesTimepoint: 10-30 days;7 duration of ICU stayTimepoint: 10-30 days	—

Countries

India

Contacts

Public ContactArun Joseph Chacko

christian medical college vellore

thambu@cmcvellore.ac.in914162282031

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026